Abstract
Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 6787-6796 |
| Number of pages | 10 |
| Journal | Biomaterials |
| Volume | 35 |
| Issue number | 25 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
Keywords
- Collagen crosslinking
- Fibrocartilage
- Integration
- Lysyl oxidase
- Tissue engineering
ASJC Scopus subject areas
- Biomaterials
- Bioengineering
- Ceramics and Composites
- Mechanics of Materials
- Biophysics
- Medicine(all)
Cite this
Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair. / Makris, Eleftherios A.; MacBarb, Regina F.; Paschos, Nikolaos K.; Hu, Jerry C.; Athanasiou, Kyriacos A.
In: Biomaterials, Vol. 35, No. 25, 2014, p. 6787-6796.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combined use of chondroitinase-ABC, TGF-β1, and collagen crosslinking agent lysyl oxidase to engineer functional neotissues for fibrocartilage repair
AU - Makris, Eleftherios A.
AU - MacBarb, Regina F.
AU - Paschos, Nikolaos K.
AU - Hu, Jerry C.
AU - Athanasiou, Kyriacos A.
PY - 2014
Y1 - 2014
N2 - Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.
AB - Patients suffering from damaged or diseased fibrocartilages currently have no effective long-term treatment options. Despite their potential, engineered tissues suffer from inferior biomechanical integrity and an inability to integrate invivo. The present study identifies a treatment regimen (including the biophysical agent chondroitinase-ABC, the biochemical agent TGF-β1, and the collagen crosslinking agent lysyl oxidase) to prime highly cellularized, scaffold-free neofibrocartilage implants, effecting continued improvement invivo. We show these agents drive invitro neofibrocartilage matrix maturation toward synergistically enhanced Young's modulus and ultimate tensile strength values, which were increased 245% and 186%, respectively, over controls. Furthermore, an invitro fibrocartilage defect model found this treatment regimen to significantly increase the integration tensile properties between treated neofibrocartilage and native tissue. Through translating this technology to an invivo fibrocartilage defect model, our results indicate, for the first time, that a pre-treatment can prime neofibrocartilage for significantly enhanced integration potential invivo, with interfacial tensile stiffness and strength increasing by 730% and 745%, respectively, compared to integration values achieved invitro. Our results suggest that specifically targeting collagen assembly and organization is a powerful means to augment overall neotissue mechanics and integration potential toward improved clinical feasibility.
KW - Collagen crosslinking
KW - Fibrocartilage
KW - Integration
KW - Lysyl oxidase
KW - Tissue engineering
UR - http://www.scopus.com/inward/record.url?scp=84902082361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902082361&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2014.04.083
DO - 10.1016/j.biomaterials.2014.04.083
M3 - Article
C2 - 24840619
AN - SCOPUS:84902082361
VL - 35
SP - 6787
EP - 6796
JO - Biomaterials
JF - Biomaterials
SN - 0142-9612
IS - 25
ER -